Modulari-T

Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in

shared product terms: any, engineer, used, modify; shared affiliation: Y Combinator

Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale.

shared product terms: cell, gene, therapy, design; same category: AI infrastructure; shared affiliation: Y Combinator

While modern AI excels in any area you can collect a lot of data for, it struggles in areas where data is sparse or costly to attain. Designing new molecules, discovering new physics, and engineering new materials are all domains where collecting data is extremely costly. We dream of a world where AI accelerates research in all of these domains and creates a more abundant future for humanity, but the current technology is not there. That’s why we started Confluence Labs. We are building AI that

shared product terms: any, area, design, engineer; same category: AI infrastructure; shared affiliation: Y Combinator

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmu

shared product terms: cancer, disease, immune, cell; same category: AI infrastructure; shared affiliation: Y Combinator

LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curativ

shared product terms: cell, therapy, gene, engineer; shared affiliation: Y Combinator

We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-N

shared product terms: any, disease, modify, expand; same category: AI infrastructure; shared affiliation: Y Combinator